Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: a case study with bedinvetmab (Librela™)
The reported clinical signs generally aligned with expected adverse events or were anticipated within the population receiving bedinvetmab. Reporting rates and patterns in general and for specific VeDDRA terms greatly varied between countries and were not related to market size. Most dogs for which adverse events were reported were considered older and in fair clinical condition. Reporting to pharmacovigilance contributes to the understanding of the safety profile of a medicinal product.
Authors
- B. Duncan X. Lascelles (ORCID: https://orcid.org/0000-0002-2950-9009)
- Oliver Knesl
- Natasha J. Olby (ORCID: https://orcid.org/0000-0003-1349-3484)
- John Innes (ORCID: https://orcid.org/0000-0003-2758-3851)
- Beatriz P. Monteiro (ORCID: https://orcid.org/0000-0002-5722-5687)
- André Simon
- Kristen Mandello
- Steven Nederveld
Institutions
- North Carolina State University (US)
- Zoetis (United States) (US)
- Carolina Veterinary Specialists (US)
Publication Details
- Journal
- Frontiers in Veterinary Science
- Published
- 2025-04-24
- DOI
- https://doi.org/10.3389/fvets.2025.1558222
- Citations
- 10
- Primary Topic
- Inflammatory mediators and NSAID effects
- Type
- article
- Field-Weighted Citation Impact
- 13.94
Funders
- Zoetis